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Tanshinone IIA induced A549 apoptosis by decreasing VEGF/VEGFR2 expression 555crystal structure of the VEGFR2 protein was evaluated with molecular docking analysis by use of the
CDOCKER algorithm in Discovery Studio 2.1. The CCK-8 results showed that tanshinone IIA can
signiﬁcantly inhibit A549 cell proliferation in a dose- and time-dependent manner. Flow cytometry results
showed that the apoptosis rate of tested group was higher than the vehicle control, and tanshinone IIA-
treated cells accumulated at the S phase, which was higher than the vehicle control. Furthermore, the
expression of VEGF and VEGFR2 was decreased in Western blot. Finally, molecular docking analysis
revealed that tanshinone IIA could be stably docked into the kinase domain of VEGFR2 protein with its
unique modes to form H-bonds with Cys917 and π–π stacking interactions with Val848. In conclusion,
tanshinone IIA may suppress A549 proliferation, induce apoptosis and cell cycle arrest at the S phase. This
drug may suppress angiogenesis by targeting the protein kinase domains of VEGF/VEGFR2.
& 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lung cancer is the most common malignant tumor. It was estimated
that 1.82 million people were diagnosed with lung cancer, and 1.6
million deaths were associated with lung cancer worldwide 20121.
The tumor response rate (tRR) of standard platinum based chemo-
therapy for advanced lung cancer is only 25%–35%, with the median
overall survival (mOS) of 8–10 months2,3.
Adriamycin (ADM), also known as doxorubicin, is a well-known
chemotherapeutic drug, the anti-cancer effect of which has been
widely afﬁrmed. Based on the effective anti-tumor effects of ADM, it
was often chosen as a positive control in experiments. However, the
serious side effects and the emergence of drug resistance are
becoming the major limitations for its application. Therefore, a search
for new anti-tumor drugs which can minimize associated toxicities to
non-cancerous tissues is on the forefront of scientiﬁc research4.
Vascular endothelial growth factor (VEGF) promotes vasculo-
genesis and angiogenesis that enhance blood vessel growth in
tissues and maintains blood supply to tissues. Overexpression of
VEGF in cancer tissues was found associated with tumor growth
and metastasis5. Therefore, a drug that is potent regulating
expression of VEGF in cancer tissues is attracting more and more
attention in the anti-cancer drug development.
Bevacizumab is the ﬁrst approved recombinant humanized
monoclonal antibody that speciﬁcally targets VEGF-A in USA6.
The review of di Costanzo et al.7 found bevacizumab plus
platinum-based chemotherapy signiﬁcantly increased mOS and
tRR compared to platinum-based chemotherapy alone in the
treatment of advanced non-small cell lung cancer (NSCLC).
A recent double-blind, multicenter, phase III trial, comprising a
total of 276 patients were randomly divided to the group of
carboplatin/paclitaxel plus bevacizumab and the group of carbo-
platin/paclitaxel plus placebo for advanced or recurrent nonsqua-
mous NSCLC. The results showed the bevacizumab group
signiﬁcantly improved the tRR (54% vs. 26%, respectively), as
well as the mOS (24.3 vs. 17.7 months, respectively) compared to
the placebo group8. Bevacizumab appeared more effective in lung
cancer patients who were VEGF-positive9. However, the toxicity
proﬁles of this drug mainly include hemorrhage, hypertension,
thrombosis and cardiac ischemia10. Therefore, a continuous search
for new anti-tumor drugs which can minimize associated toxicities
to non-cancerous tissues is on the forefront of scientiﬁc research.
Salvia miltiorrhiza Bunge is the dry root and rootstock of
salvias and known as ‘Danshen’ in traditional Chinese medicine.
In tradition, S. miltiorrhiza Bunge has been used for promotingblood circulation, removing blood stasis, clearing away toxic
material, relieving restlessness and eliminating edema11. Modern
pharmacological studies ﬁnd that the active ingredients of S.
miltiorrhiza Bunge have pro-cardiovascular effects such as
expanding the coronary artery, increasing blood ﬂow in the
coronary artery, anti-oxidant, anti-inﬂection, liver protection,
immunity regulation and anti-tumor effect.
Tanshinone IIA (Tan IIA) is one of the main fat-soluble
compositions in the root of red-rooted salvia (Fig. 1). The anti-
tumor effect of Tan IIA includes inhibiting tumor cell prolifera-
tion, disturbing tumor cell cycle, promoting tumor cell apoptosis,
and inhibiting tumor cell invasion and transfer11,12.
In various cancer cell studies, researchers11–16 found the antitumor
effect and anti-angiogenic effect of Tan IIA were associated with
inhibiting the expression of VEGF. These studies also showed
inhibiting the expression of VEGF did not appear in normal cells.
While there has been a lot of research on the relationship
between Tan IIA and the expression of VEGF, whether Tan IIA
has an inﬂuence on the combination of VEGF and its receptors in
lung cancer metastasis remains unclear. Therefore, we proposed
that the Tan IIA's antitumor effect may be associated with the
regulation of VEGF/VEGFR signal pathway. We conducted the
present study to explore the mechanism of Tan IIA-induced
inhibition of tumor progression and regulated angiogenesis via
VEGF/VEGFR signaling pathway in the NSCLC cell line A549.2. Materials and methods
2.1. Materials
The human non-small cell lung cancer A549 cell line was
purchased from the Cell Bank of the Chinese Academy of
Sciences (Shanghai, China). Tan IIA (1,6,6-trimethyl-6,7,8,9-
tetrahydrophenanthro[1,2–b]furan-10,11-dione Danshen ketone,
C19H18O3, 497% HPLC) was purchased from Sigma-Aldrich
(St. Louis, USA), and prepared as a 10 mmol/L stock solution in
dimethylsulfoxide (DMSO, Sigma-Aldrich). The solution was kept
in dark and 20 1C, and serially diluted in a RPMI 1640 medium
immediately prior to experiments. Adriamycin hydrochloride
(C27H29NO11, 98.0%–102.0% HPLC) was purchased from
Sigma-Aldrich and prepared as a 13.79 mmol/L stock solution in
normal saline (NS). The solution was kept in dark and 20 1C
and serially diluted in a RPMI 1640 medium immediately prior to
experiments. RPMI1640 medium and fetal bovine serum (FBS)
Figure 1 The structure of tanshinone IIA (from PubChem compound).
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Pancreatin was supplied by Gibco (Carlsbad, USA). Cell Counting
Kit-8 (CCK-8) was purchased from Dojindo Molecular Techno-
logies Inc. (Kumamoto, Japan). The Annexin V‑FITC apoptosis
detection kit and KeyGEN DNA content quantitation assay (cell
cycle) were obtained from KeyGEN BioTECH (Nanjing, China).
Rabbit anti-human VEGF monoclonal antibody, rabbit anti-human
VEGFR2 monoclonal antibody, rabbit anti-human GAPDH poly-
clonal antibody and goat anti-rabbit horseradish peroxidase (HRP)-
conjugated secondary antibody are obtained from Cell Signaling
Technology (Beverly, USA).
2.2. Cell line and cell culture
A549 cell line were cultured in RPMI1640 medium, supplemented
with 10% FBS in a humidiﬁed incubator at 37 1C with 5% CO2
atmosphere. Cells in logarithmic phase will be used in the experiment.
2.3. Detection of the anti-proliferative effect of Tan IIA
A549 cells were counted in logarithmic phase and 6000 cells (90 μL
volume) were placed in 96-well plates. 10 μL varying concentrations
of Tan IIA (ﬁnal concentrations 80, 60, 40, 30, 20, 15, 10, 5 and
2.5 μmol/L) and ADM (ﬁnal concentrations 8, 4, 2, 1, 0.5 and
0.25 μmol/L) were added into drug groups, while negative control
group (vehicle group) was only added 10 mL DMSO or normal saline
without Tan IIA or ADM. Cells were incubated for an additional 2 h
with CCK-8 reagent (100 μL/mL medium) and the absorbance was
read at 450 nm using a microplate reader (BioTek, Winooski, 126 VT,
USA). Cell proliferation inhibition rates were calculated according to
the following formula: the proliferation inhibition ratio (%)¼1
[(A1A4)/(A2A3)] 100, where, A1 is the OD value of drug
experimental group, A2 is the OD value of blank control group, A3 is
the OD value of the RPMI1640 medium without cells, and A4 is the
OD value of drugs with the same concentration as A1 but without
cells. The IC50 (50% inhibitory concentration) value, which represents
the concentration of the drug that demonstrates 50% of cell growth
inhibition, was calculated by nonlinear regression analysis using
GraphPad Prism software (San Diego, USA).
2.4. Morphological changes of A549 cells
A549 cells (105 cells/mL, 2 mL in 6-well plates) were grown to 70%
conﬂuence, and Tan IIA and ADM were added in ﬁnal concentra-
tions of 31 μmol/L and 2.5 μmol/L (IC50 value for 48 h) respectively,along with control and vehicle groups. Morphological changes of
A549 cells were observed by optical microscope every 12 h.
2.5. Cell apoptosis measurements by ﬂow cytometry (FCM)
Designated cells (105 cells/mL, 2 mL/well) were allowed to adhere
and yield 80% conﬂuence. Cells were then treated with 31 μmol/L
Tan IIA for 48 h. To exclude the impact of the DMSO solution, we
added an equal volume of DMSO in the vehicle group, and an
equal volume of RPMI1640 medium in the blank control group.
Cells were collected by centrifugation and washed twice with ice-
cold PBS. The collected cells were then resuspended in 200 μL of
binding buffer and incubated with 5 μL each of Annexin V-FITC
and propidium iodide (PI) for 15 min in the dark, at room
temperature, per the manufacturer's instructions. The cells were
analyzed immediately after staining, using a FACScan ﬂow
cytometer (Becton-Dickinson). For each measurement, at least
20,000 cells were counted. Each experiment was repeated 3 times.
2.6. Cell cycle studies using ﬂow cytometry
Cells were counted in logarithmic phase (105 cells/mL, 2 mL in 6-
well plates), which were synchronized by medium exposure, with a
low concentration of FBS for 24 h for the induction of cell cycle
arrest. The culture medium was then replaced with a nutrient-rich
medium, and the cells in Tan IIA group were treated with 31 μmol/L
Tan IIA for 48 h. The grouping methods and drug treatments were
the same as above. Cells were then harvested, washed twice with
cold PBS and ﬁxed with 75% cold ethanol at 4 1C for 24 h. Cells
were then incubated with RNase A (50 mg/mL) at 37 1C for 30 min
then labeled with propidium iodide (PI, 0.1 mg/mL) followed by
incubation at room temperature in the dark for 30 min prior to
analysis. For each measurement, at least 20,000 cells were counted.
Fluorescence intensity of the stained cells was measured using ﬂow
cytometry (Beckman Coulter, USA). Data were analyzed using
ModFit (Verity Software House, Inc., Topsham, USA). These
experiments were repeated 3 times.
2.7. VEGF and VEGFR2 protein expression with Western blot
A549 cells treated with Tan IIA (31 μmol/L) and ADM (2.5 μmol/L)
for 48 h were collected, along with blank and vehicle groups. Cells
were rinsed twice with PBS and lysed in ice-cold lysis buffer for
30 min with occasional rocking. The lysates were clariﬁed by
centrifuging them at 12,000 rpm, for 5 min at 4 1C. The protein
concentration of each supernatant was determined using the BCA kit
(Cwbiotech，Beijing, China). Analysis was performed with 8% SDS-
PAGE separation gel and 60 μg proteins were transferred to PVDF
membrane. The membrane was blocked using blocking buffer for 2 h
at room temperature, and incubated overnight at 4 1C with speciﬁc
primary antibodies (VEGF, 1:1000; VEGFR2, 1:500; GAPDH,
1:2000). Subsequently, the membrane was washed three times with
TBST buffer and incubated with horseradish peroxidase (HRP)-
conjugated secondary antibodies (1:1000) for 1 h at room temperature,
and washed extensively before detection. The membranes were
subsequently developed using enhanced chemiluminescence reagent
(Millipore, Billerica, USA) and exposed to ﬁlm according to the
manufacturer's protocol. GAPDH was used as the internal reference.
Relative optical density (ROD, ratio to GAPDH) of each blot band was
quantiﬁed by using National Institutes of Health (NIH) image software
(Image J 1.36b).
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To predict the potential interaction of Tan IIA and the VEGFR2
protein, the CDOCKER module in Discovery Studio (DS) 2.1
(Accelrys Software Inc., San Diego, USA) was applied to our
molecular docking algorithm. The three dimensional (3D) crystal
structure of VEGFR2 was selected from PDB (http://www.rcsb.
org/pdb/) with an ID of 3VHE. The 3D structure of Tan IIA was
downloaded from The PubChemProject (http://www.pubchem.
ncbi.nlm.nih.gov/) with a CID of 164676. The DS2.1 was run
using a localhost9943 server.
VEGFR2 and Tan IIA docking procedure includes the follow-
ing steps. First, preparation for Tan IIA and VEGFR2: the water
molecules in the protein were removed and the hydrogen atoms
were added to the receptor protein. VEGFR2 and Tan IIA were
reﬁned with CHARMm respectively. Secondly，the active site of
VEGFR2 was deﬁned by two methods: one is according to internal
ligand’s binding site, the other is deﬁned automatically with DS
2.1, and then selected by relevant references. Thirdly, Tan IIA was
docked into the active site of 3O96 with proper parameter setting
and a series of algorithm.
Speciﬁc docking procedures were as follows by CDOCKER: the
grid origin was located at the center of the active site of VEGFR2 with
a minimum of 21.0Å or the largest ligand dimension þ5.0Å as the
side length. A grid spacing of 0.5Å was used. For each deﬁned van
der Waals force (vdW) or electrostatic probe, the interactions with all
protein atoms were stored at these grid points. For ligand atoms
located between grid points, a tri-linear interpolation was used to
approximate the energies. A harmonic potential with the force constant
of 300 kcal/mol was applied outside the grid boundary. Starting from
the Tan IIA of input conﬁguration, 10 different orientations were
randomly generated by translating the center of the ligand to the grid
within the receptor active site, and performing a series of random
rotations, and then docked into the protein (3O96), i.e., moved into the
center of the grid. Each orientation was subjected to simulated
annealing molecular dynamics simulation. A molecular dynamics
(MD) simulation was run consisting of a heating phase from 300 to
700 K with 2000 steps, followed by a cooling phase back to 300 K
with 5000 steps. The energy threshold for vdW was set at 300 K. We
further reﬁned the simulation result by running a short energy
minimization, consisting of 50 steps of steepest descent followed by
up to 200 steps of conjugate gradient using an energy tolerance of
0.001 kcal/mol.
2.9. Statistical analysis
Statistical analyses were performed with mean7standard devia-
tion (SD) values using Student's t-test and two-way analysis of
variance (ANOVA) with the Bonferroni's correction. Statistical
signiﬁcance was concluded at Po0.05.3. Results
3.1. Anti-proliferative effects on cells
Both Tan IIA and ADM had anti-proliferative effects on A549 cells.
The effects were dose- and time-dependent, with more pronounced
effects being observed following higher concentrations and after
longer exposure times. At the same time, the effect of ADM was
more obvious than that of Tan IIA: the IC50 of ADM after 24, 48 and
72 h were 14.36, 2.34 and 0.99 μmol/L, respectively. In contrast,IC50 values for Tan IIA were 145.3, 30.95 and 11.49 μmol/L,
respectively (Fig. 2A and B).
3.2. Effects of Tan IIA and ADM on A549 morphology
Obvious apoptosis and cell growth inhibition of A549 cells were
observed after drug treatment for 48 h (concentrations used were
approximately IC50 values: Tan IIA 31 μmol/L or ADM 2.5 μmol/L
on A549). The morphology changes included blebbing, loss of cell
membrane asymmetry, attachment and cell shrinkage (Fig. 3).
3.3. Effects of Tan IIA on apoptosis
Drug-induced apoptosis was tested with the Annexin V/PI double dye
kit. Annexin V can combine with cytomembrane in early stage of
apoptosis while PI can enter cells in the middle or advanced stage of
apoptosis and combine with the cell nucleus. FCM analyses yielded
cell histograms consisting of four quadrants (Fig. 4). The dots in the
upper left quadrant represent the injured cells during the process of
collecting cells. The dots in the lower left quadrant represent normal
cells. The dots in the upper right quadrant represent apoptotic cells in
advanced stage and necrotic cells. And the dots in the lower right
quadrant represent apoptotic cells in early stage. Thus, the ratio of
apoptotic cells in each group should be the sum of the ratio of the
upper right and lower right quadrants. As a result, the ratios of
apoptotic cells in blank control group, vehicle control group and Tan
IIA group respectively were: 11.27%, 11.12% and 22.22%. The
laboratory ﬁndings revealed: only a small part of cells go to apoptosis
in the blank control group and the results exhibited no signiﬁcant
differences between the blank control group and vehicle group,
indicating good condition of the cells. After a 48 h treatment with
Tan IIA (31 μmol/L), the ratio of cell apoptosis in the Tan IIA group
increased (Po0.001 vs. the vehicle group, Fig. 4).
3.4. Effects of Tan IIA on cell cycle
Cell cycle experiments were performed with the DNA quantitation
assay. The results found that following 48 h of exposure, the cell
cycle distribution of blank group and vehicle groups exhibited no
signiﬁcant difference, demonstrating that DMSO at very low
concentrations had no obvious effect. In A549 cells, after 48 h
of exposure to Tan IIA (31 μmol/L), the ratio of cells in G1 stage
and G2 stage decreased while the ratio in S stage increased vs.
vehicle. However, none of these changes achieved statistical
signiﬁcance except the S phase arrest (Po0.05), indicating that
Tan IIA may have inhibiting effect on A549 cells in S stage
(Fig. 5).
3.5. Effect of Tan IIA on VEGF/VEGFR2 protein expression
Western blotting found that 48 h exposures to Tan IIA (31 μmol/L)
or ADM (2.5 μmol/L) in A549 cells, downregulated expression of
VEGF and VEGFR2 protein in both drug treatment groups vs.
vehicle (Fig. 6). Protein expression was not changed signiﬁcantly
in the blank and vehicle groups.
3.6. Virtual docking technique simulates the approach of the
interaction between Tan IIA and VEGFR2
Docking calculations via the CDOCKER docking module in DS2.1
can accurately simulate the docking of small molecules to the active
Jun Xie et al.558sites of macromolecules. After docking with endogenous ligand by
CDOCKER, the root-mean-square deviation (RMSD) is medially
about 0.35Å. While the RMSD, after docking again with endogen-
ous ligand by LigandFit, is medially about 0.91Å, which indicates
the root-mean-square of the ligand calculated by CDOCKER module
has less displacement as compared to the endogenous ligand in
single crystal diffraction diagram. Thus, the docking results calcu-
lated by CDOCKER module are more accurate, supporting our
choice of CDOCKER for the present work.
Using the protein crystal structure of VEGFR2 and its binding site
in the PDB database permitted a resolution of the 3VHE three-
dimensional structure at 1.55Å (Fig. 7A). This structure, consisting
of 359 amino acid residues and a peptide chain, contains the protein
kinase structural domain of VEGFR2. In this structural domain, there
is a new inhibitor that belongs to pyrrole pyrimidines. In addition toFigure 3 Effect of tanshinone IIA and adriamycin on morphology of A5
adriamycin (2.5 μmol/L) for 48 h and then observed under optical microsc
Figure 2 Inhibitive effects of adriamycin and tanshinone IIA respective
adriamycin (A) and tanshinone IIA (B) for 24, 48 and 72 h, then assayed bythe endogenous ligand binding site, automatic searching of DS2.1.
revealed 7 active sites. Characterization of site1 (Fig. 7B) shows a
large overlap with the endogenous ligand-binding region. Integration
of these results with related articles conﬁrms the binding site of the
endogenous ligand as the binding site being presently explored. The
center of a region reachable by an appropriate small molecule would
include the amino acid residues, whose radius is less than 5Å are:
Leu840, Glt841, Val848, Ala866, Val867, Lys868, Glu885, Ile888,
Leu889, Ile892, Val898, Val899, Val914, Val916, Gle917, Phe918,
Cys919, Lys920, Phe921, Gly922, Asn923, Leu1019, Cys1024,
Ile1025, His1026, Leu1035, Ile1044, Cys1045, Asp1046 and
Phe1047.
Simulations of the approach of Tan IIA and its protein binding
site revealed 10 conﬁgurations (Fig. 7C). Tan IIA can dock stably
with the kinase structural domain of the endogenous ligand binding49 cells. A549 cells were treated with tanshinone IIA (31 μmol/L) or
ope.
ly on A549 cells. Cells were treated with different concentrations of
CCK8 method. Data were derived from three independent experiments.
Figure 4 Effect of tanshinone IIA on apoptosis of A549 cells. The apoptotic status was determined with Annexin V/PI staining method. Representative
FCM proﬁles of cells were shown by a cytometric analysis. The drug-treated cells showed signiﬁcantly increased apoptosis. ***Po0.001 vs. vehicle.
Tanshinone IIA induced A549 apoptosis by decreasing VEGF/VEGFR2 expression 559site (Fig. 7C). In this kinase structural domain, the two amino acid
residues, Val848 and Cys917, are related to the interaction between
Tan IIA and VEGFR2. All of the 10 conﬁgurations of Tan IIA can
form hydrogen bond with Cys917 and in the meantime the 10 poses
can form π–π interaction with Val848 (Fig. 7D).4. Discussion
In this study, ADM was used as a positive control to ensure the
accuracy of the methods and experimental design. In addition,
equivalent volumes of DMSO were used in the negative control
groups. As explained earlier, the CCK8 method was used to
investigate A549 cell proliferation, and the FCM used to explore
cell apoptosis and cycle changes. The ﬁndings indicate that Tan
IIA and ADM have remarkable inhibitory effects on A549 cell
proliferation which are in a dose- and time-dependent manner.
Most importantly, Tan IIA at a concentration of 31 μmol/L can
induce apoptosis and S phase arrest.
Our ﬁnding of Tan IIA-induced A549 cells' apoptosis is consistent
with other studies12,17–19. Tung's research16 found that, the proteins
involved in the S to M phase transition were suppressed by Tan I or
Tan II treatment (1, 5, 10 and 25 μmol/L Tan I for 24 h) in human
lung adenocarcinoma cell lines (A549, CL1-0 and CL1-5), indicating
that Tan I and Tan II are likely to slow the progression of cells
through the S and G2 phases of the cell cycle. Wei et al.20 found that
when the renal cancer cell line 786-O cells were treated with Tan IIA
(0, 2, 4 and 8 μg/mL) for 24 h, the percentage of cells in the S phasewas 10.0%, 11.5%, 20.4% and 23.3%, indicating that Tan IIA
treatment induces S phase arrest in 786-O cells.
There are disagreements across laboratories over effects of these
drugs on the cell cycle. Ma and others21 hold the view that Tan IIA
causes G0/G1-phase cell-cycle arrest in the NSCLC cell line H1299
cells. These experiments showed that treatment of H1299 cells with
Tan IIA (4 μmol/L) for 48 h, the proportion of cells at the G0/G1
phase increased more than 10% as compared with the control.
Based on these ﬁndings, we propose that different doses of Tan
IIA on different cells may result in different cell cycle effects at
different post-treatment times. We propose that low doses of Tan
IIA may contribute to cell cycle arrest at the G1 phase after short
treatment time, whereas higher doses of Tan IIA may lead to S
phase blockade after longer exposure time. However, there is not
enough published data to support a powerful conclusion on the cell
cycle effects caused by Tan IIA.
In recent decades, scientists have found that VEGF can stimulate
vascular endothelial cell division and proliferation, inhibit cell
apoptosis, increase vascular permeability, and promote revasculariza-
tion and angiogenesis in different tissues. Cell-dependent VEGF
signaling relies on the speciﬁc membrane receptors Flt-1, VEGFR2
and VEGFR3. VEGF activates the tyrosine kinase after combining
with the receptors outside cells, and then promotes receptor phospho-
rylation and the ensuing signal transduction mechanisms. The overall
impact of VEGF in endothelial cells is controlled by combinations
with Flt-1 and VEGFR2. VEGF B exerts its function via Flt-1 while
VEGF C and VEGF D exert their function via VEGFR2 and
VEGFR3. sFlt-1 and sVEGFR2 have strong antagonistic effects
Figure 5 Effect of tanshinone IIA on cell cycle of A549 cells. Representative FCM proﬁles of cells were shown by a cytometric analysis. The
drug-treated cells showed small difference in S phase. *Po0.05 vs. vehicle.
Figure 6 Effect of tanshinone IIA and adriamycin respectively on VEGF and VEGFR2 expression of A549 cells. Western-blot assay showed that the drug-
treated A549 cells had signiﬁcantly difference on the expression level of VEGF and VEGFR2, compared to vehicle group. ***Po0.001, **Po0.01 vs. vehicle.
Jun Xie et al.560against VEGF. These soluble receptors can combine with VEGF and
interdict its biological activity, destroying the integrity and perme-
ability of vascular walls, thereby attenuating angiogenesis. VEGF has
strong afﬁnity for both Flt-1 and VEGFR2. The activity of Flt-1
tyrosine kinase is only one tenth of that of VEGFR2. This receptor can
exert strong biological effects after stimulation22. It is known that
VEGFR2 controls the signal transduction of VEGF.
Since the present results found that the expression of VEGF and
VEGFR2 in A549 cells declined after treatment of Tan IIA
(31 μmol/L) after 48 h, we suggest that the mechanism of TanIIA induction of A549 cell apoptosis might be associated with Tan
IIA's inhibition of VEGF and VEGFR2 expression, thereby
interdicting the combination of VEGF and VEGFR2, and blocking
the VEGF/VEGFR signal pathway. Such effects would inhibit the
generation of new vessels of tumor cells.
This hypothesis is consistent with the results of other researchers
studying the anti-tumor cell effect of Tan IIA. Their ﬁndings showed
that Tan IIA can inhibit cell proliferation, angiogenesis, migration
and tube formation of human umbilical vascular endothelial cells.
Techniques used included chorioallantoic membrane (CAM), rat
Figure 7 Interaction of tanshinone IIA and VEGFR-2 protein. (A) The 3D structure of crystal structure of human VEGFR-2 (3VHE) with a
kinase domain Inhibitor. The solid ribbon is the 3D structure of crystal structure of 3VHE with a 1.55Å resolution. In the center of 3VHE is a
kinase domain inhibitor bound in the interface. (B) The binding site1 of 3VHE through auto-searching of DS2.1 (green). (C) The 10 poses from
tanshinone IIA were docked into the endogenous ligand’s active site of VEGFR-2. (D) Ten random poses of tanshinone IIA binding to the
endogenous ligand's active site of 3VHE presented at least 2 residues involved in the interactions potentially: H-bonds with Cys917, aromatic
interactions with Val848.
Tanshinone IIA induced A549 apoptosis by decreasing VEGF/VEGFR2 expression 561aortic ring assays and Western blotting. Xing et al.15 reached the
conclusion that Tan IIA may inhibit endothelial cell function via the
simultaneous inhibition of the VEGF/VEGFR2 signaling pathway
and regulation of MMP-2/-9 production.
Tung et al.16 found that both Tan I and Tan II can attenuate lung
tumorgenesis via inhibition of VEGF, cyclin A and cyclin B
expressions in A549, CL1-0 and CL1-5 cell lines. The authors
concluded that blockade of the tumor-activated cell cycle pathway
may be a critical mechanism for the observed antitumorigenic effects
of Tan I and Tan II treatment on vasculogenesis and angiogenesis.
Won et al.23 found that Tan IIA-induced apoptosis involves
mitochondria intrinsic caspase activation cascade and an inhibition
of the PI3K/AKT survival pathway in prostate cancer cells.
Therefore, we propose that Tan IIA might act via suppression of
the VEGF/VEGFR signal pathway in tumor cells, indirectly
inhibiting downstream PI3K/AKT signaling pathway, up-
regulating the expression of apoptosis-promoting gene, down-
regulating the expression of anti-apoptosis gene, thereby inhibiting
the growth of tumor cells and promoting apoptosis.The PI3K/AKT signal path is an important function in cell growth,
migration, invasion and apoptosis, which has multiple activation
mechanisms, including VEGF. The combination of VEGF and the
receptor VEGFR2 can activate PI3K/AKT/Forkhead signal pathways
in endothelial cells, and consequently inhibit cell apoptosis, promote
DNA production and accelerate the transformation of cell cycle from
the G1 stage to the S stage24.
Collectively, Tan IIA may be an inhibitor of the VEGF/
VEGFR2. It regulates MMP-2/-9 secretion and stimulates the
relative cyclin and apoptin. Tan IIA also indirectly inhibits
downstream the PI3K/AKT signal pathway, and overall contri-
butes to the anti-angiogenic activity, cell proliferation inhibition,
and pro-apoptosis effects. Although the mechanisms of Tan IIA's
effects on the NSCLC cell line, and the genes relevant to VEGF
and VEGFR2 remain to be fully explored, this is a promising
direction for further research.
It is notable that Yang and others25 found that Tan IIA could
up-regulate the expression of VEGF and SDF-1 in rats' bone
marrow-derived endothelial progenitor cells (EPCs), probably
Figure 8 Molecular mechanisms of effect of tanshinone IIA in the
VEGF/VEGFR signaling pathway. In vascular endothelial cells, after
the VEGF combined with VEGFR2, tanshinone IIA binds to the
VEGFR2 kinase domain, blocking the downstream pathways of
VEGF/VEGFR.
Jun Xie et al.562promoting EPCs homing better in ischemic conditions and
facilitating the effective repair of vessels.
Therefore, we propose that Tan IIA may protect normal cells,
but inhibit cancer cells. However, further validation of this
hypothesis is required.
In the ﬁnal stages of this work, we simulated the mode of
interaction between Tan IIA and targeted proteins by the virtual
docking research platform. The methods were optimized by use of
the results of molecular biological experiments. We focused on the
analysis of the possible binding mode of Tan IIA and VEGFR2.
The inhibitor actions which target the VEGF/VEGFR pathway are
divided into 2 categories at present: (1) combining with VEGF to
block its interaction with the receptor. For example, antibody
soluble receptors and nucleic acid drugs respectively combine with
VEGF in protein and nucleic acid level to inhibit angiogenesis. (2)
Targeting VEGFR directly, such as antibody and inhibitors of
tyrosine kinase receptor26. As Tan IIA is a small molecule
compound, the strategy of our experiment is to target the tyrosine
kinase region of VEGFR2 directly.
In PDB database, the three-dimensional structure of 3VHE,
whose resolution ratio is 1.55Å, consists of a peptide chain that
includes 359 amino acid residues. It contains VEGFR2 protein
kinase structural domain, in which there is a new pyrrole
pyrimidine derivatives inhibitor27. The RMSD is 0.35Å after
docking again with endogenous ligand by CDOCKER module in
DS2.1. Site1, the binding site we found by DS2.1 automatically
searching, can cover the structural domain included by endogen-
ous ligand. We found, after molecule docking in two ways, Tan
IIA docking with the binding site of endogenous ligand is more
stable. The active site of the docking of Tan IIA and VEGFR2
(PDB ID: 3VHE) may be deﬁned as the structural domain of the
binding site of endogenous ligand, according to related refer-
ences28. This domain, whose radius is 9.5Å, contains the kinase
domain of VEGFR2. Tan IIA can stably dock with the kinase
structural domain of the binding site of endogenous ligand
(Fig. 7D). In this kinase structural domain, two amino acid
residues, Val848 and Cys917, involve with the interaction between
Tan IIA and VEGFR2. The 10 conﬁgurations of Tan IIA can form
hydrogen bond with Cys917 and π–π interaction with Val848
(Fig. 7D). Considering the present experiments along with the
results of Won and others23, we suggest that Tan IIA may, via
inhibition of the VEGF/VEGFR signal pathway, inhibit the
downstream PI3K/AKT signal pathway indirectly, up-regulate
the expression of apoptosis-promoting genes, down-regulate the
expression of anti-apoptosis genes, thereby inhibiting the growth
and promoting tumor cell apoptosis. Therefore, there is strong
support for the hypothesis that Tan IIA is a tyrosine kinase
inhibitor of VEGFR2.
In summary, our study revealed that the mechanism of Tan IIA's
anti-tumor effects may be related to inhibition of tumor angiogenesis,
as a tyrosine kinase inhibitor of VEGFR2 (Fig. 8). It might interdict
VEGF/VEGFR signal pathways, leading to cell cycle arrest and
suppressing downstream signal pathway indirectly, then up-regulating
the expression of apoptosis-promoting genes, down-regulating the
expression of anti-apoptosis genes, and ﬁnally inhibiting the growth
and promoting the apoptosis of tumor cells.
Based on our ﬁndings, we propose that Tan IIA could have
considerable therapeutic effects in inhibiting tumor growth,
angiogenesis and metastasis. In conclusion, the presence of Tan
IIA may be a promising alternative therapy for NSCLC. This study
otherwise suggests a new research approach to examine the active
agents in traditional Chinese medicine in inhibiting tumor growth.Acknowledgment
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